Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.49 (market cap $16.72B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: iShares 3 7 Year Treasury Bond ETF is far larger — about 149× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| IEI | INO | |
|---|---|---|
Market Cap | $16.72B | $112.19M |
Volume | 3,963,319 | 3,201,278 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $2.65 |
52-Week Low | $113.17 | $0.66 |
Typical Hold Time | 43 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.49 with minimal daily movement, up 0.1%. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. Recent corporate actions include consistent dividend payments. The bond market environment, highlighted by rising Treasury yields, influences sentiment, with news pointing to volatility in interest rates affecting fixed-income related assets.
The outlook remains cautious due to bearish technical signals and macroeconomic pressures from rising yields. Investment opportunities include dividend consistency, but risks involve interest rate sensitivity and market volatility. A neutral to bearish stance is warranted pending clearer fundamental data or stabilization in bond markets.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
